Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 46

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 3
Chunk 46
---
 or exercisable within 60 days of March 17, 2025, of which options to purchase the following number      
           of shares expire on the following dates, respectively: 11,250 on March 30, 2032 and 3,750 on November 20, 2034. The weighted average exercise  
           price of these options is NIS 32.83 per ordinary share. Also includes 2,050 shares issuable upon vesting of RSUs that are currently vested     
           or will become vested within 60 days of March 17, 2025, all of which expire on March 8, 2033, and with no exercise price.                      
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (3)      Consists of 2,500 ordinary shares of Evogene issuable upon exercise of options that are currently exercisable or exercisable within          
           60 days of March 17, 2025, which expire on September 1, 2031. The exercise price of these options is NIS 91.7 per ordinary share. Elran      
           Haber serves as the CEO of our subsidiary company Biomica, and as such, also holds options to purchase shares of Biomica. For a description  
           of our subsidiaries’ equity incentive plans, please see “ Item 6. Directors, Senior Management and Employees— B. Compensation— Share         
           Option and Incentive Plans— Subsidiary Equity Incentive Plans”.                                                                              
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  (4)      Consists of 16,250 ordinary shares issuable upon exercise of options that are currently exercisable or exercisable within 60 days            
           of March 17, 2025, of which options to purchase the following number of shares expire on the following dates, respectively: 3,000 on August  
           8, 2027, 750 on July 30, 2029, 7,000 on September 1, 2031, 3,000 on March 8, 2033 and 2,500 on November 20, 2034. The weighted average       
           exercise price of these options is NIS 81.36 per ordinary share.                                                                             
 ─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────